Monday, November 29, 2021 Daily Archives

CDMO round-up: Lonza, Abzena, and Samsung deals

by

BlueJay Therapeutics selects Lonza to manufacture its HBV antibody candidate; BiVictriX contracts Abzena; Samsung Biologics will manufacture drug substance for GreenLight’s mRNA COVID-19 vaccine candidate. Great to have you here for BioProcess Insider’s CDMO round-up. First up in our contract development manufacturing organization (CDMO) round-up is Swiss company Lonza, which BlueJay Therapeutics recently selected to provide a tailored program to support production of BJT-778 a monoclonal antibody (mAb) drug candidate targeting chronic hepatitis B virus (HBV) infection. Under terms of…

November 29, 2021

Omicron variant disrupts Thanksgiving for COVID vaccine firms

by

Moderna says it will know whether its current mRNA vaccine protects against the Omicron variant within two weeks. Discovered in South Africa last week, the B.1.1.529 variant – named Omicron – has become a concern in the fight against COVID-19 due to its large number of mutations. “[There are] at least 30 in the spike protein alone, with nine of them known to be associated with immune escape and another 11 predicted to be associated with immune escape. You bring…

November 29, 2021